NeoGenomics, Inc. Reports Record Revenue Of $18.3 Million, Adjusted EBITDA Of $2.7 Million And Net Income Of $0.02 Per Share For The Fourth Quarter 2013

FT. MEYERS, Fla., Feb. 19, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013.

Fourth Quarter 2013 Highlights:

-- Revenue growth of 23%

Help employers find you! Check out all the jobs and post your resume.